| Catalog No. |
TD-VK539036 |
| Description |
Libivirumab is a human monoclonal antibody directed against the hepatitis B virus. Libivirumab had an IC50 of 35 and 128 ng/ml in the neutralization assays based on ELISA and immunofluorescence assays. |
| Species reactivity |
Hepatitis B virus genotype A (HBV-A) |
| Applications |
Research Grade Biosimilar |
| Host species |
Human |
| Isotype |
IgG1, kappa |
| Expression system |
Mammalian Cells |
| Clonality |
Monoclonal |
| Target |
Large envelope protein, L glycoprotein, L-HBsAg, LHB, Large S protein, Large surface protein, Major surface antigen, S |
| Endotoxin level |
Please contact the lab for this information. |
| Purity |
>95% purity as determined by SDS-PAGE. |
| Purification |
Protein A/G, purified from cell culture supernatant. |
| Accession |
P03142 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS,pH7.4. |
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Alternate Names |
17.1.41,HepeX-B(combinationofexbivirumabandlibivirumab),CAS:569658-79-3 |
| Background |
Libivirumab (17.1.41) is a human anti-HBV monoclonal antibody. Libivirumab shows neutralization activity with IC50s of 35, 130 ng/mL for HBsAg, HBeAg, respectively. |
| Note |
For research use only. Not for use in clinical or therapeutic applications. |